67. Fujiwara S, Morita Y, Toyonaga T et al. A randomized controlled trial of rebamipide plus rabeprazole for the healing of artifcial ulcers after endoscopic submucosal dissection. J. Gastroenterol. 46 (5), 595-602 (2011).
68. Fujimoto K, Hongo M; Maintenance Study Group. Safety and effcacy of long-term maintenance therapy with oral dose of rabeprazole 10 mg once daily in Japanese patients with refux esophagitis. Intern. Med. 50(3), 179-188(2011).
69. Rindi G, Fiocca R, Morocutti A, Jacobs A, Miller N, Thjodleifsson B; European Rabeprazole Study Group. Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. Eur.J. Gastroenterol. Hepatol. 17 (5), 559-566 (2005).
70. Salgueiro E, Rubio T, Hidalgo A, Manso G. Safety profle of proton pump inhibitors according to the spontaneous reports of suspected adverse reactions. Int. J. Clin. Pharmacol. Ther. 44 (11), 548-556 '(2006).
71. Ishizaki T, Horai Y Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment. Pharmacol. Ther. 13 (Suppl. 3), 27-36 (1999).
72. Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases.Aliment. Pharmacol. Ther. 13 (Suppl. 3), 18-26 (1999).
73. Hata M, Hayasaka M, Sezai A et al. Proton pump inhibitors may increase the risk of delayed bleeding complications after open heart surgery if used concomitantly with warfarin. Thorac. Cardiovasc. Surg. 56 (5), 274-277 (2008).
* * Study of 240 patients taking warfarin after heart surgery suggesting that, in contrast to lansoprazole, which emphasizes the effects of warfarin, rabeprazole could be safely used concom itantly.
74. Coudsy B, Funck-Brentano C, Blanchard A et al. Effect of rabeprazole on the antiplatelet action of clopidogrel, a prospective, randomized, 3-way crossover PK/PD study in healthy subjects. Gut 60 (Suppl. 3), A264 (2011).
* Pharmacokinetic/pharmacodynamic study showing that rabeprazole 20 mg is noninferior to placebo as related to clopidogrel antiplatelet activity, while omeprazole is not.
75. Sharara A, Malli A, El-Halabi M et al The effect of CYP2C19 genetic polymorphisms and the concomitant use of rabeprazole or esomeprazole on the antiplatelet action of clopidogrel. Am. J. Gastroenterol. 106 (2), S37-S38(2011).
* * Clinical trial in patients receiving a stable dose of clopidogrel with or without rabeprazole or esomeprazole in which rabeprazole, in contrast to esomeprazole, does not appear to exert any measurable effect on clopidogrel activity.
76. Kinoshita Y, Matsumoto N, Watanabe M et al. Comparison of the effects of omeprazole and rabeprazole on ticlopidine metabolism in vitro. J. Pharmacol. Sci. 117(1), 19-26 (2011).
77. Gilard M, Arnaud B, Cornily JC et al. Infuence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J.Am. Coll. Cardiol. 51 (3), 256-260 (2008).
78. Fernando H, Bassler N, Habersberger J et al. Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. J. Thromb. Haemost. 9 (8), 1582-1589(2011).
79. Bhatt DL, Cryer BL. Contant CF et al.; COGENT Investigators. Clopidogrel with or without omeprazole in coronarv artery disease.N. Engl.J. Med. 363 (20), 1909-1917 (2010).
80. Angiolillo DJ, Gibson CM, Cheng S et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin. Pharmacol. Ther. 89 (1), 65-74 (2011).
81. Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a metaanalysis of randomized clinical trials. Clin. Gastroenterol. Hepatol. 4(12), 1452-1458(2006).
82. Sheu BS, Cheng HC, Chang WL, Chen WY, Kao AW. The impact of body mass index on the application of on-demand therapy for Los Angeles grades A and В refux esophagitis. Am. J. Gastroenterol. 102 (11), 2387-2394 (2007).
83. Sheu BS, Chang WL, Cheng HC, Kao AW, Lu CO Body mass index can determine the healing of refux esophagitis with Los Angeles Grades С and D by esomeprazole. Am. J. Gastroenterol. 103 (9), 2209-2214 (2008).